|
|
|
|
Written by George Loizou
|
|
Monday, 22 June 2009 |
 ![]() HSL is to run a two-day course on the Derivation of a Derived No-Effect Level Using PBPK and Benchmark Dose Response Modelling.
The course will be held at the Health and Safety Laboratory, Harpur Hill, Buxton, Derbyshire on the following dates: Tuesday 15 June 2010 – wednesday 16 June 2010 The course will cover: - Tools for use in quantitative, data-informed chemical risk assessment.
- An approach for the derivation of a DNEL for a chemical with a demonstrable threshold.
- The fundamental concepts underlying PBPK modelling.
- The rapid construction of PBPK models using a user-friendly model equation generator and visualizing model output using the software, Berkeley Madonna®.
Who should attend? - Industrial professionals responsible for conducting or evaluating risk assessments on consumer, environmental and occupational exposure to chemicals.
- Occupational health and safety professionals.
- Scientists interested in physiologically based pharmacokinetic modelling.
Venue The course will be run at the HSL laboratory in the spa town of Buxton. Buxton is in the heart of the Peak District and has good links to mainline train stations and Manchester International Airport. The cost of the two-day course is £995 + VAT (includes course notes, lunches, dinner on the Monday night and all refreshments). For further information Click here or contact the Training Unit at HSL directly on +44 1298 218806. |
|
Last Updated ( Wednesday, 16 December 2009 )
|
|
|
Written by Martin Spendiff
|
|
Wednesday, 01 July 2009 |
 The Hamner Institutes for Health Sciences is offering a Computational Systems Biology and Dose Response Modeling Workshop on September 14 - September 18, 2009. The description of the workshop can be located at The Hamner Website.
|
|
Last Updated ( Wednesday, 01 July 2009 )
|
|
Read more...
|
|
|
Written by George Loizou
|
|
Friday, 27 March 2009 |
|
Eurotox 2009 - Dresden, Germany Symposium 6 (WHO/International Programme on Chemical Safety) Tuesday, September 15 The increasing use of pharmacokinetic models in chemical risk assessments is recognised. It is necessary to develop a common understanding of what constituents are required to develop an internationally acceptable model and how to validate it. A common understanding would facilitate sharing of models and model evaluations as well as consistent application in risk assessments. Consideration will be given to:
1) Model development,
2) Model characterization, i.e. methods to describe how consistent the model is with biology; strengths and limitations of available model and data, such as sensitivity analyses,
3) Model documentation,
4) Model evaluation, i.e. independent review.
Presentations by Dr. Bette Meek, Canada, Prof. Dr. Ursula Gundert-Remy, Germany, Dr. George Loizou, UK, Dr. Harvey J. Clewell III, USA, Dr. Olavi Pelkonen, Finland
|
|
Last Updated ( Friday, 03 April 2009 )
|
|
|
Written by Martin Spendiff
|
|
Wednesday, 13 May 2009 |
Cyprotex has recently launched Cloe® Gateway, a new secure web portal for access to drug discovery services. The initial offering via Cloe® Gateway is a new enhanced version of our proprietary predictive software, Cloe® PK, which predicts whole body pharmacokinetics from simple in vitro ADME and physicochemical properties.
|
|
Last Updated ( Thursday, 14 May 2009 )
|
|
Read more...
|
|
|
Written by Conrad Housand
|
|
Wednesday, 16 January 2008 |
 AEgis recently announced substantial price reductions for the acslX family of tools for modeling and simulation, which are widely used for PBPK and PK/PD modeling. The full version, which includes textual and graphical languages for specifying complex kinetics/dynamics models, and a Matlab-like scripting language for specification of parameter estimation, sensitivity analysis, Monte-Carlo, or Markov-Chain Monte Carlo analyses, is now priced starting at $500 US. The price reduction is intended to make acslX accessible to a wider community of modelers seeking an affordable high-end commercial simulation tool, and to increase the audience of potential end-users of models developed by current acslX customers. The latest version of acslX includes support for cluster/grid computing, and provides data integration capabilities with Microsoft Excel and Access. A PBPK/PK/PD toolkit is also available, and a Bayesian population modeling capability based on MCMC analysis is planned for early this year. Contact
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
for more information, or visit www.acslx.com.
|
|
Last Updated ( Wednesday, 23 January 2008 )
|
|
|
Written by Martin Spendiff
|
|
Wednesday, 30 April 2008 |
From Simcyp:
We have a number of immediate openings for scientists with drug metabolism and pharmacokinetics background. The candidates should have hands-on experience in using any of the in vitro systems used for assessing the oral absorption, distribution, metabolism and excretion (ADME) of drugs. Knowledge of pharmacological effects, human physiology and biology, and in particular modelling and data analysis is advantageous.
The successful applicant will join an internationally recognised, multidisciplinary team in which s/he will be expected to take part in building information around in vitro in vivo extrapolation of ADME properties and indicating its applications.
|
|
Last Updated ( Friday, 09 May 2008 )
|
|
Read more...
|
|
| | << Start < Prev 1 2 Next > End >>
| | Results 1 - 7 of 10 |
|
|
|
|
|
